CMS Issues Sanctions to Elevance Health: Impacts on Medicare Advantage Plans
On February 27, the Centers for Medicare & Medicaid Services (CMS) issued a sanctions notice to Elevance Health, a major U.S. health insurer and Blue Cross Blue Shield licensee. The notice warned of a potential suspension of new enrollments in Medicare Advantage plans starting March 31 due to alleged non-compliance in risk adjustment data submission. This led to a decrease in Elevance's stock value to $292.16, approaching its 52-week low.
Elevance responded by reaffirming its 2026 adjusted earnings per share (EPS) guidance of at least $25.50, incorporating the potential impacts of the CMS sanctions. CFO Mark Kaye stated at the Barclays 28th Annual Global Healthcare Conference on March 10 that the company does not anticipate the sanctions affecting their capital deployment priorities or 2026 planned actions, which include a $5.5 billion operating cash flow target and a $2.3 billion share buyback plan.
Further strategic efforts include Elevance's aim for a 12% adjusted EPS growth in 2027. This optimism is driven by strategic adjustments in Medicare Advantage offerings, pricing modifications in Medicaid, and the expansion of Carelon Services, which provides specialty pharmacy and behavioral health services.
The CMS notice impacts Elevance as it navigates financial management under regulatory scrutiny. However, the firm emphasizes that its adjusted EPS floor already factors in such challenges, indicating a resilience despite the imposed sanctions. The share value reflects these risks, suggesting that Elevance's guidance has fully considered them.
Forecasts suggest that the normalized EPS could reach $26.01 in 2026, potentially rising to $29.44 by 2027 due to improved Medicare Advantage margins and strategic adjustments. Additionally, free cash flow is projected to surge to $4.97 billion in 2026, up from $3.17 billion in 2025, as delayed Medicaid payments are resolved.
Analysts present a mean target price for Elevance at $380.95, forecasting significant upside potential. Variances in analyst targets indicate different risk scenarios based on the duration of CMS sanctions, with high estimates relying on prompt solutions and successful growth in external health management services.
In a sign of confidence, Steven H. Collis, a director at Elevance, made a notable stock purchase shortly after the sanctions notice. Management has reiterated that their initial quarterly performance is exceeding previous expectations. Upcoming financial reports in April are anticipated to offer further insights into the impact of CMS sanctions, focusing on key metrics like Medicare expense ratios and Medicaid trends.